How Long Does Allergy Immunotherapy Take? SCIT vs. SLIT Compared

Head-to-head meta-analyses show comparable efficacy between SCIT and SLIT for commercialized single-allergen products. Tie et al. (Laryngoscope 2022) synthesized direct-comparison adult RCTs and found symptom SMD of -0.02 (95% CI -0.15 to 0.11) and medication SMD of -0.14 (95% CI -0.31 to 0.03) — statistically indistinguishable between modalities. For grass and dust mite, where FDA-approved SLIT tablets exist, current evidence supports therapeutic equivalence. SCIT retains potential advantages for polysensitized patients needing custom multi-allergen mixes, which have no FDA-approved SLIT equivalent. SLIT's safety profile — 83% lower adverse event rates in pediatric meta-analyses — is decisively better than SCIT's for the allergens where both are comparably effective.

Yes — cluster and rush protocols compress the build-up phase significantly. Cluster immunotherapy delivers 2-3 injections per visit on non-consecutive days, achieving maintenance in approximately 4-8 weeks rather than 4-6 months (Calabria, Ann Allergy Asthma Immunol 2023). Rush immunotherapy completes build-up in 1-3 days with injections every 15-60 minutes under continuous hospital monitoring. Both carry higher per-injection systemic reaction rates than conventional weekly build-up — cluster approximately 3-fold higher (Chen et al., Ann Allergy 2023), rush substantially higher and requiring premedication. Omalizumab pretreatment (Casale et al., JACI 2006) reduced anaphylaxis during ragweed rush by approximately 5-fold. Cluster protocols are the most commonly used acceleration approach in outpatient practice because they balance speed with manageable safety risk.

Allergy shots require dramatically more clinic visits — approximately 150 visits over a 5-year course, including weekly visits during the 6-month build-up and monthly visits throughout maintenance, each requiring a mandatory 30-minute post-injection observation period. Sublingual drops typically require only 2-4 telehealth check-ins per year after the initial prescription and first-dose supervised administration — approximately 10-20 total appointments over 5 years. Hankin et al. (JACI 2013) identified this visit burden as a major driver of SCIT costs and adherence challenges. For patients with demanding work schedules, young children, or limited transportation, this difference is often the decisive factor in treatment choice.

Sublingual immunotherapy shows comparable onset of clinical benefit to allergy shots — most patients notice improvement within 3-6 months of reaching maintenance dose. Because SLIT reaches maintenance in days rather than months, the total calendar time from starting treatment to first improvement can be shorter than SCIT (3-6 months from day one for SLIT versus 6-12 months from day one for SCIT). Chelladurai and Durham (Immunol Allergy Clin N Am 2016) confirmed comparable onset at 3-6 months in head-to-head meta-analyses. FDA-approved SLIT tablets for grass pollen (Grastek, Oralair) have demonstrated statistically significant symptom score improvement within the first treatment season in large phase III trials.

Stopping either SCIT or SLIT before completing at least 3 years at maintenance significantly reduces post-treatment durability. The EAACI guideline (Roberts et al., Allergy 2018) explicitly states that 2-year courses are insufficient for sustained post-treatment benefit, and minimum 3 years is required. Patients who stop at 12-18 months of maintenance may retain some benefit but are substantially more likely to relapse than those who complete the full course. The immune mechanisms driving post-treatment durability — regulatory T-cell tolerance and IgG4-producing B-cell memory — require sustained allergen exposure to become firmly established. Early stopping is the most common reason for suboptimal outcomes in real-world immunotherapy cohorts, where median SCIT persistence is only 1.7 years per Kiel et al. (JACI 2013).

Investigational approaches are exploring compressed immunotherapy timelines, but none offer a proven shortcut to lasting benefit yet. Intralymphatic immunotherapy (ILIT) delivers allergen directly into inguinal lymph nodes under ultrasound guidance — Senti et al. (PNAS 2008) showed 3 injections over 2 months produced measurable immunological and clinical effects in birch-allergic patients, though larger confirmatory trials are ongoing. Epicutaneous immunotherapy (EPIT) via allergen-coated patches shows promise for peanut allergy and is in clinical trials for aeroallergens. Oral immunotherapy (OIT) is established for peanut allergy but raises tolerability and desensitization-vs-tolerance questions for aeroallergens. None of these approaches has demonstrated the 3-12 year post-treatment durability established for SCIT or the emerging post-treatment data for SLIT.